TG Therapeutics (TGTX) Projected to Post Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) is expected to announce its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect TG Therapeutics to post earnings of $0.24 per share and revenue of $152.1150 million for the quarter. TG Therapeutics has set its FY 2025 guidance at EPS.Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Monday, November 3, 2025 at 8:30 AM ET.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.15). The firm had revenue of $141.15 million during the quarter, compared to analyst estimates of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business’s quarterly revenue was up 92.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.04 EPS. On average, analysts expect TG Therapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

TG Therapeutics Stock Up 2.2%

Shares of TG Therapeutics stock opened at $34.78 on Friday. TG Therapeutics has a 1-year low of $22.92 and a 1-year high of $46.48. The company has a market capitalization of $5.52 billion, a PE ratio of 94.00 and a beta of 1.97. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96. The business has a 50-day moving average of $33.45 and a 200-day moving average of $34.87.

Wall Street Analyst Weigh In

TGTX has been the subject of a number of recent analyst reports. HC Wainwright assumed coverage on TG Therapeutics in a research note on Monday, October 6th. They set a “buy” rating and a $60.00 price objective for the company. B. Riley increased their target price on TG Therapeutics from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of TG Therapeutics in a research report on Wednesday, October 8th. Finally, The Goldman Sachs Group raised shares of TG Therapeutics to a “hold” rating and set a $37.00 price target on the stock in a report on Thursday, July 10th. Three research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $48.75.

Insider Activity

In related news, Director Sagar Lonial sold 20,852 shares of the firm’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the transaction, the director directly owned 94,061 shares in the company, valued at $3,032,526.64. This trade represents a 18.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 10.64% of the company’s stock.

Institutional Trading of TG Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TGTX. Engineers Gate Manager LP boosted its holdings in shares of TG Therapeutics by 138.2% in the 2nd quarter. Engineers Gate Manager LP now owns 17,492 shares of the biopharmaceutical company’s stock valued at $630,000 after buying an additional 10,148 shares during the period. Advisory Services Network LLC lifted its holdings in TG Therapeutics by 66.3% in the second quarter. Advisory Services Network LLC now owns 20,205 shares of the biopharmaceutical company’s stock worth $717,000 after acquiring an additional 8,054 shares during the last quarter. E Fund Management Co. Ltd. boosted its stake in TG Therapeutics by 23.6% in the second quarter. E Fund Management Co. Ltd. now owns 21,009 shares of the biopharmaceutical company’s stock valued at $756,000 after acquiring an additional 4,013 shares during the period. Boothbay Fund Management LLC grew its holdings in shares of TG Therapeutics by 16.3% during the second quarter. Boothbay Fund Management LLC now owns 71,051 shares of the biopharmaceutical company’s stock valued at $2,557,000 after purchasing an additional 9,963 shares during the last quarter. Finally, Royal Bank of Canada raised its position in shares of TG Therapeutics by 16.4% during the 1st quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company’s stock worth $2,985,000 after purchasing an additional 10,660 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.